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Abstract
This is the official guideline endorsed by the specialty associations involved in the care of head and neck cancer
patients in the UK. A rational plan to manage the neck is necessary for all head and neck primaries. With the
emergence of new level 1 evidence across several domains of neck metastases, this guideline will identify the
evidence-based recommendations for management.
Recommendations
• Computed tomographic or magnetic resonance imaging is mandatory for staging neck disease, with choice of
modality dependant on imaging modality used for the primary site, local availability and expertise. (R)
• Patients with a clinically N0 neck, with more than 15–20 per cent risk of occult nodal metastases, should be
offered prophylactic treatment of the neck. (R)
• The treatment choice of for the N0 and N+ neck should be guided by the treatment to the primary site. (G)
• If observation is planned for the N0 neck, this should be supplemented by regular ultrasonograms to ensure
early detection. (R)
• All patients with T1 and T2 oral cavity cancer and N0 neck should receive prophylactic neck treatment. (R)
• Selective neck dissection (SND) is as effective as modified radical neck dissection for controlling regional
disease in N0 necks for all primary sites. (R)
• SND alone is adequate treatment for pN1 neck disease without adverse histological features. (R)
• Post-operative radiation for adverse histologic features following SND confers control rates comparable with
more extensive procedures. (R)
• Adjuvant radiation following surgery for patients with adverse histological features improves regional control rates. (R)
• Post-operative chemoradiation improves regional control in patients with extracapsular spread and/or microscopically
involved surgical margins. (R)
• Following chemoradiation therapy, complete responders who do not show evidence of active disease on co-registered
positron emission tomography–computed tomography (PET–CT) scans performed at 10–12 weeks, do not need
salvage neck dissection. (R)
•Salvage surgery should be considered for thosewith incomplete or equivocal response of nodal disease onPET–CT. (R)
Introduction
The presence, site and size of metastatic neck disease
are important prognostic factors in head and neck
squamous cell cancer. Head and neck tumours have
a propensity to metastasise to neck nodes and
several factors control the natural history and spread
of disease. Controversy surrounds the management
of the neck in head and neck squamous cell cancer.
This is primarily due to the paucity of high-level evi-
dence for many treatment paradigms, but this trend
may be reversing with randomised controlled trials
and systematic reviews published recently and a few
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more in progress. This section discusses the manage-
ment of neck metastases at initial presentation and for
residual or recurrent neck disease. It outlines major
clinical controversies regarding the management of
occult and overt metastatic squamous cell carcinoma
(SCC) to the neck nodes.
Assessment and staging
For the purpose of assessment and documentation, the
neck is described in six anatomical levels, (Table I).
Level VII is relevant for some head and neck
tumours and is included in the table for completeness.
Clinical palpation
Clinical palpation is regarded as inaccurate (sensitivity
and specificity 70–80 per cent) due to factors including
inter-operator variability, shape of neck, absence or
presence of significant subcutaneous fat and varying
size of involved cervical nodes.
Computed tomographic (CT) and magnetic resonance
imaging (MRI) scanning
These techniques have similar sensitivity (81 per cent)
in detecting metastatic disease, with CT demonstrating
better specificity.1 Co-registered positron emission
tomography–computed tomography scanning (PET–
CT) has been shown to alter initial staging in up to
one-third of patients, but the value of this is unclear.
This technique has higher sensitivity in picking up clin-
ically occult primaries, synchronous second primaries
and distant metastases. PET-CT has demonstrated
high negative predictive values in the assessment of
neck disease after organ preservation regimes.
Ultrasound (US) scanning and US-guided fine needle
aspiration cytology (FNAC)
Ultrasound has been demonstrated to have consistent-
ly high sensitivity (87 per cent) in diagnosing meta-
static neck disease. Ultrasound-guided FNAC
requires both expertise and experience, and has very
high specificity rates (98 per cent) in diagnosis. It
should be noted that there are no absolute ultrasound
characteristics for differentiating benign from malig-
nant disease.
Sentinel node biopsy
The aim of this technique is to identify and excise the
echelon nodes using radioscintigraphy, which are
then tested for occult disease. Patients with no occult
disease in the sentinel nodes receive no further treat-
ment for the neck. Meta-analyses suggest that sentinel
node biopsy has sensitivity rates exceeding 90 per
cent.2,3 A recent prospective multicentre study that
recruited 415 patients with 0.5–4 cm transorally resect-
able SCC and an N0 neck, showed that sentinel node
biopsy had a sensitivity, negative predictive value and
false negative rate of 86, 95 and 14 per cent, respective-
ly.4 Oncological outcomes were not compromised
despite only 94 of 415 patients undergoing neck dissec-
tion in this cohort.
Recommendation
• Computed tomographic or MR imaging is
mandatory for staging neck disease, with
choice of modality dependent on imaging
modality used for the primary site, local
availability and expertise (R)
Neck nodal stage
This should be confirmed and documented in the
case record after imaging (certainty factor 2) and
prior to treatment planning, using the N category in
the 7th edition of the TNM Classification of
Malignant Tumours, Union for International Cancer
Control (UICC) cancer staging manual. Table II
shows the N category to stage neck metastases
arising from all head and neck sites excluding
those of the nasopharynx, thyroid gland and
mucosal melanomas.
Treatment options
Surgery
Historically the mainstay of surgical management of
metastatic neck has been neck dissection in its
various forms. The standardised neck dissection ter-
minology produced by the American Academy of
Otolaryngology and Head and Neck Surgery in 1991
has been updated by the Committee for Neck
Dissection Classification of the American Head and
Neck Society in 20025 (Table III). There is an increas-
ing trend to divide neck dissections into two broad
types with subdivisions: comprehensive (removal of
levels I–V) and selective (less than five levels). The
need for less extensive surgery in the chemoradiation
era, with neck dissection procedures that cannot be
classified under the existing systems has led to calls
for revision of this system.6
It is recommended that the levels or sublevels
removed during selective neck dissection (SND) be
precisely stated in the operation notes. In order to min-
imise confusion within labelling the levels during pro-
cessing, the neck dissection specimen should be
divided according to the levels in the operating room
and sent to the laboratory in different containers. An
alternative is to orientate the neck dissection specimen
on a suitable base and label the levels with a marking
pen, with or without a photograph, and send it to the
laboratory. There is good evidence for reduced long-
term morbidity with SND compared with the compre-
hensive types, namely modified radical neck dissection
(MRND) and radical neck dissection (RND). Surgical
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therapy must be delivered within accredited multidis-
ciplinary teams, by members regularly involved in
caring for head and neck cancer patients.
Radiotherapy
Radiotherapy (RT) should be delivered within an
accredited department using megavoltage photons
typically from a linear accelerator (typical energy
6 MV). Similar principles should be used for selecting
the nodes for RT as are described above for surgery.
The probability of microscopic involvement of other
nodal groups rises with increasing T-stage and this
leads to larger volumes of tissue-requiring irradiation.
Radiotherapy to the neck requires adequate immobil-
isation and a five-point fixation shell is recommended.
Computed tomography scanning in the treatment pos-
ition provides the anatomical and electron density infor-
mation required for RT planning. Conventional and
three-dimensional conformal RT often require the use
of multiple phases of treatment using photons and elec-
trons of appropriate energy. These techniques have now
been superseded by intensity modulated radiotherapy
(IMRT), particularly where bilateral nodal irradiation
TABLE I
LYMPH NODE LEVELS, SUBLEVELS AND BOUNDARIES
Level Clinical location Surgical boundaries Radiological boundaries
Ia Submental triangle S: Symphysis of mandible
I: Hyoid bone
A (M): Left anterior belly of digastric
P (L): Right anterior belly of digastric
Nodes above the level of lower body of hyoid bone,
below mylohyoid muscles and anterior to a
transverse line drawn through the posterior edge of
submandibular gland on an axial image
Ib Submandibular
triangle
S: Body of mandible
I: Posterior belly of digastric
A (M): Anterior belly of digastric
P (L): Stylohyoid muscle
IIa Upper jugular S: Lower level of bony margin of jugular fossa
I: Level of lower body of hyoid bone
A (M): Stylohyoid muscle
P (L): Vertical plane defined by accessory nerve
Superior and inferior limits as described under
surgical boundaries
Nodes posterior to a transverse plane defined by the
posterior surface of submandibular gland and
anterior to a transverse line drawn along the
posterior border of the sternomastoid.
NOTE: Nodes lying medial to the carotids are
retropharyngeal and not level II
IIb Upper jugular S: Lower level of bony margin of jugular fossa
I: Level of lower body of hyoid bone
A (M): Vertical plane defined by accessory
nerve
P (L): Posterior border of sternomastoid muscle
III Mid Jugular S: Level of lower body of hyoid bone
I: Horizontal plane along inferior border of
anterior cricoid arch
A (M): Lateral border of sternohyoid muscle
P (L): Posterior border of sternocleidomastoid
muscle or sensory branches of the cervical
plexus
Superior and inferior limits as described under
surgical boundaries
Nodes anterior to a transverse line drawn on each
axial scan through the posterior edge of the SCM
and lateral to the medial margin of the common
carotid arteries
IV Lower jugular S: Horizontal plane along inferior border of
anterior cricoid arch
I: Clavicle
A (M): Lateral border of sternohyoid muscle
P (L): Posterior border of sternocleidomastoid
muscle or sensory branches of the cervical
plexus
Superior and inferior limits as described under
surgical boundaries
Nodes anterior to a transverse line drawn on each
axial scan through the posterior edge of the SCM
and lateral to the medial margin of the common
carotid arteries
Va Posterior triangle S: Convergence of SCM and trapezius muscles
I: Horizontal plane along inferior border of
anterior cricoid arch
A (M): Posterior border of sternocleidomastoid
muscle or sensory branches of the cervical
plexus
P (L): Anterior border of trapezius muscle
Nodes posterior to a transverse line drawn on each
axial scan through the posterior edge of the SCM
Vb Posterior triangle
(supraclavicular)
S: Horizontal plane along inferior border of
anterior cricoid arch
I: Clavicle
A (M): Posterior border of sternocleidomastoid
muscle or sensory branches of the cervical
plexus.
P (L): Anterior border of trapezius muscle
VI Anterior
compartment
S: Hyoid bone
I: Sternal notch
A (M): Common carotid artery
P (L): Common carotid artery
VII Superior
mediastinum
S: Sternal notch
I: Innominate artery
A (M): Common carotid artery
P (L): Common carotid artery
S= superior; I= inferior, A= anterior; P= posterior, L= lateral; M=medial; SCM= sternocleidomastoid
NECK METASTASES IN HEAD AND NECK CANCER: UK GUIDELINES S163
http://dx.doi.org/10.1017/S002221511600058X
Downloaded from http:/www.cambridge.org/core. University of Birmingham, on 11 Oct 2016 at 11:21:54, subject to the Cambridge Core terms of use, available at http:/www.cambridge.org/core/terms.
is indicated, where it has been shown to be associated
with a reduced risk of late xerostomia and has become
the standard of care.
There is now increasing use of concomitant chemo-
radiotherapy following publication of level 1 studies,
suggesting that use of chemoradiotherapy improves
overall and progression free survival in advanced head
andneck cancer both in the primaryandpost-operative set-
tings. Altered fractionation regimes have also been shown
to offer some advantage over standard fractionation.
Management strategies for the various neck
nodal stages
Treatment of cervical lymph nodes is either elective (in
the clinically negative neck) or therapeutic (in the clin-
ically positive neck).
Management of the clinically node negative neck (N0)
New primary. Clinical and radiological examinations are
unable to detect microscopic disease in lymph nodes.
Several large retrospective series have reported the inci-
dence of metastases found on histological examination
after RNDs in patients with clinically node negative
(N0) necks. These figures are useful in identifying the
risk of occult metastases in N0 necks and are used to
guide clinicians when deciding whether prophylactic
treatment of the neck is appropriate (Figure 1).
A study of risk–benefit analysis made in the 1990s
using data from retrospective series, when RND was
the only procedure widely used for elective neck treat-
ment, suggested that prophylactic treatment of the neck
was required if the risk of occult nodal metastases rose
above 20 per cent. Given the low morbidity of either
available treatment modality, there is support for elect-
ive treatment for lesser risk (5–15 per cent). Primary
sites with greater than 15 per cent risk of occult meta-
static disease in the neck would include almost all squa-
mous cancers of the upper aerodigestive tract except T1
and T2 cancers of the glottis and selected T1 cancers of
the oral cavity.
A recent randomised controlled trial (RCT) reported
on 500 patients with lateralised stage T1 or T2 oral
SCCs randomised to elective neck dissection (n=
245) or observation and intervention (n= 255), with
a median follow up period of 39 months.7 At three
years, elective node dissection resulted in an
improved rate of overall survival (80.0 per cent;
95 per cent confidence interval (CI), 74.1 to 85.8), as
compared with therapeutic dissection (67.5 per cent;
95 per cent CI, 61.0 to 73.9), with a hazard ratio for
death of 0.64 in the elective-surgery group (95 per
cent CI, 0.45 to 0.92; p= 0.01 by the log-rank test).
Patients in the elective-surgery group also had a
higher rate of disease-free survival than those in the
therapeutic-surgery group (69.5 per cent vs 45.9 per
TABLE II
TUMOUR–NODE–METASTASIS CLASSIFICATION OF
REGIONAL NODES
Nx Regional lymph nodes cannot be assessed
N0 No regional lymph node metastases
N1 Metastasis in a single ipsilateral lymph node 3 cm or less in
greatest dimension
N2 Metastasis in a single ipsilateral lymph node, more than
3 cm but not more than 6 cm in greatest dimension, or in
multiple ipsilateral lymph nodes none more than 6 cm in
greatest dimension, or in bilateral or contralateral lymph
nodes, none more than 6 cm in greatest dimension
N2a Metastasis in a single ipsilateral lymph node, more than
3 cm but not more than 6 cm in greatest dimension
N2b Metastasis in multiple ipsilateral lymph nodes, none more
than 6 cm in greatest dimension
N2c Metastasis in bilateral or contralateral lymph nodes, none
more than 6 cm in greatest dimension
N3 Metastasis in a lymph node more than 6 cm in greatest
dimension
Note: Midline nodes are considered to be ipsilateral nodes
TABLE III
CLASSIFICATION OF NECK DISSECTION TECHNIQUES
Radical neck
dissection (RND)
Removal of levels I–V, accessory nerve,
internal jugular vein and sternomastoid
muscle
Modified radical
neck dissection
Removal of levels I–V dissected;
preservation of one or more of the
accessory nerve, internal jugular vein
or sternomastoid muscle (types I, II,
III, respectively)
Selective neck
dissection
Preservation of one or more levels of
lymph nodes
Extended radical
neck dissection
Removal of one or more additional
lymphatic and/or non-lymphatic
structures(s) relative to a RND, e.g.
level VII, retropharyngeal lymph
nodes, hypoglossal nerve FIG. 1
Algorithm for management of the N0 neck.
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cent, p< 0.001). A meta-analysis of all previously
published RCTs including data on 283 patients
showed that elective neck dissection reduced the
risk of disease-specific death (fixed-effects model
relative risk= 0.57, 95 per cent CI 0.36–0.89, p=
0.014; random-effects model relative risk= 0.59,
95 per cent CI 0.37–0.96, p= 0.034) compared with
observation.8
The classical RND has no role to play in elective
treatment of the N0 neck.9 The choice lies between an
MRND and an SND. Prospective studies suggest
SND is as effective as MRND for most primary sites
with minimal morbidity. Table IV shows the suggested
neck levels that should be addressed for various primary
sites, with the recommendations based on a recent ana-
lysis of the evidence base.9 For oral cavity tumours,
SND of levels I to III should be performed. Due to
the possibility of skip lesions in level IV, especially in
tongue tumours, some studies recommend including
level IV. In oropharyngeal, laryngeal and hypopharyn-
geal tumours, SND of levels II–IV should be per-
formed. Level IIb dissection may not be necessary for
the majority of patients, as the incidence of isolated
metastasis at this site is less than 2 per cent.10
Elective neck irradiation is as effective as elective neck
dissection in controlling subclinical regional disease,
with control rates reported to be around 90 per cent.
When the primary tumour is treated with RT, first
echelon lymph nodes, which are at the greatest risk of
harbouring occult disease, are usually included in the
high dose or radical RT treatment volume. A large retro-
spective series comparing elective neck dissection and
elective neck irradiation in patients with oral cavity, oro-
pharyngeal and laryngeal cancer reported no statistically
significant difference in local control at five years. In
patients with hypopharyngeal cancers, local control
was significantly better with RT compared with
surgery. The consensus guidelines drawn up by experts
from clinical research organizations within Europe,
Asia, Australia/New Zealand and North America, pub-
lished in 2014, should be followed for delineation of
lymph nodal levels in the node negative neck.11
Large retrospective series have reported on the risk
of contralateral nodal involvement by each anatomic
tumour subsite. As in ipsilateral N0 necks, the contra-
lateral neck should be treated if the estimated risk of
occult spread exceeds 15–20 per cent, as occurs with
tumours encroaching or crossing the midline. Elective
nodal irradiation may be preferred to surgery when
both sides of the neck are to be treated.
In long-term follow-up of the untreated N0 neck,
consideration should be given where available to ultra-
sound surveillance and ultrasound-guided aspiration
cytology as a method of detecting and treating early
disease before it becomes clinically palpable.12
Recurrent primary cancer. Occult metastatic rates are
low (5–10 per cent) in the setting of radiorecurrent
cancer if the neck has been included in the radiation
field. As neck dissection (ND) in the salvage setting
is associated with more complications with no reported
benefit, if access to the neck vessels is not needed for
primary resection or reconstruction, routine elective
neck dissection may not be needed during salvage
surgery for locally recurrent primary cancers.
Recommendations
• Patients with a clinically N0 neck, with more
than 15–20 per cent risk of occult nodal
metastases, should be offered prophylactic
treatment of the neck (R)
• The treatment choice of the N0 neck should be
guided by the treatment to the primary site (G)
• If observation is planned for the N0 neck, this
should be supplemented by regular
ultrasonograms to ensure early detection (R)
• All patients with T1 and T2 oral cavity cancer
and N0 neck should receive prophylactic neck
treatment (R)
• Selective neck dissection is effective as MRND
for controlling regional disease in N0 necks
for all primary sites (R)
• Elective neck dissection and elective neck
irradiation have equal efficacy in controlling
occult neck disease (R)
Management of the clinically node positive neck
When there is clinical or radiological evidence of
disease in neck lymph nodes, active treatment is
required. Level 1 studies exist to guide the treatment
of metastatic neck disease in specific scenarios
(Figures 2 and 3). The risk of occult metastases in
other apparently uninvolved levels of the neck is
high, and depending on the primary site, treatment
of these nodes is also required. Level V is least
likely to be involved, with between 3 and 7 per cent
of patients undergoing RND having positive nodes
at level V. The treatment choice of the N+ neck
should be guided by the treatment to the primary
site, and there is long-term data to support this
premise.13
TABLE IV
RECOMMENDED NECK LEVELS TO BE DISSECTED FOR
OCCULT NECK DISEASE BASED ON PRIMARY SITE
Oral cavity I–III including IIb
Oropharynx I–III including IIb; recognise significant chance
of contralateral disease
Supraglottis IIa–III; IIb and IV can be spared. Contralateral
SND not indicated for lateralised tumours
Glottis IIa–III; IIb can be spared. Include IV for T3 and
T4 primaries
Subgottis II–IV, VI
Hypopharynx II–IV
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N1 neck disease. Prospective data from large cancer
databases suggest that single modality therapy is suf-
ficient to deal with ipsilateral, single nodes of less
than 3 cm in size. If surgery is the chosen modality,
SND may be appropriate. As approximately 50 per
cent of clinically N1 necks are upstaged after patho-
logical assessment, many patients subsequently
require post-operative radiation. Prospective studies
have shown that in the absence of bulky disease
(N1, N2b), appropriate SND in combination with
FIG. 3
Algorithm for management of the N+ neck when chemoradiation is the primary modality.
FIG. 2
Algorithm for management of the N+ neck when surgery is the primary modality.
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postoperative RT result in neck control rates equiva-
lent to those achieved by comprehensive neck dissec-
tion.9 Complete response rates are much higher in
patients with nodes of less than 3 cm in size and
regional control rates following RT alone are best in
patients with nodes less than 2 cm in size.
N2 and N3 neck disease. If the primary modality is
surgery for this stage of neck disease, MRND and
RND result in equivalent rates of disease control in
the neck when performed in appropriately selected
patients.9 Retrospective and prospective studies
suggest that adding irradiation post-operatively
increases regional control,14 especially in the presence
of adverse features such as extracapsular nodal spread,
positive margins, pT3 or pT4 primary, pN2 or pN3
nodal disease, nodal disease in levels IV or V, peri-
neural invasion and vascular invasion. Randomised
controlled trials from the EORTC and RTOG have
shown improved control with chemoradiotherapy in
the post-operative setting, especially in the presence
of extracapsular spread and/or microscopically
involved surgical margins.15 Patients with two or
more histopathologically involved lymph nodes
without extracapsular spread as their only risk factor
did not benefit from the addition of chemotherapy.
Morbidity of neck irradiation is higher in patients
who have undergone an RND.
If the primary site is suitable for non-surgical treat-
ment, the neck should be treated at the same time. For
neck disease staged N2 and above, this will usually
involve chemoradiotherapy. The PET-Neck phase III
randomised trial compared PET–CT-guided active
surveillance with planned neck dissection for neck
disease staged N2 or N3 treated by chemoradiother-
apy. The study recruited 282 patients into each arm
and showed that the survival outcomes were similar
with a minimum follow up of two years. A post treat-
ment PET–CT surveillance strategy led to fewer neck
dissections, fewer complications, was cost effective
(per person cost saving of £1415) and provided 0.07
additional quality adjusted life years compared with
planned neck dissection. Based on the results of the
PET-Neck trial, there is no role for planned neck dis-
section after primary chemoradiotherapy.16 The
current standard of care should be a CT–PET scan
between 10 and 12 weeks following chemoradiother-
apy, with ND being offered to those who show incom-
plete or equivocal response of nodal disease.
Complete responders may need no further interven-
tion.17 The extent of the salvage neck dissection can
be based on local protocols, with the recognition
that there is an increasing trend to perform a limited
neck clearance in these individuals, with removal of
the involved level alone or an adjacent level. In
patients with fixed and unresectable nodal disease,
RT or chemoradiotherapy will be the only options
available, but a low likelihood of curative outcome
should be recognised.
If the primary tumour is small but sited where resec-
tion is not feasible, and associated with advanced neck
disease, resection of the nodal disease followed by treat-
ment of the primary tumour by RT (± chemotherapy)
plus post-operative RT to the involved neck could poten-
tially be considered but this will be associated with a sig-
nificant delay in the management of the primary disease
which may result in interval primary disease progression.
Recommendations
• The treatment choice to the N+ neck
should be guided by the treatment to the
primary site (G)
• Selective neck dissection alone is adequate
treatment for pN1 neck disease without
adverse histological features (R)
• Post-operative radiation for adverse histologic
features following SND confers control rates
comparable to more extensive procedures (R)
• Adjuvant radiation following surgery for
patients with adverse histological features
improves regional control rates (R)
• Post-operative chemoradiation improves
regional control in patients with extracapsular
spread and/or microscopically involved
surgical margins (R)
Assessing treatment response
Neck node size and fixity predict response rate and local
control with RT alone. In patients with clinical N2 or N3
disease, there is poor correlation between clinical and
pathological response following chemoradiotherapy. As
discussed above, the PET-Neck trial demonstrated
equivalent survival rates to planned neck dissection,
with a lower morbidity and a higher overall cost-effective-
ness. Co-registered PET–CT scans, performed at least 10
weeks after treatment is now considered the standard of
care. A negative PET–CT scan following treatment por-
tends a high disease free survival.18 High standard uptake
values are associated with residual disease and this can be
used to decide the need for neck dissection following
primary chemoradiotherapy.17,19,20
Recommendations
• Following chemoradiation therapy, complete
responders who do not show evidence of
active disease on co-registered PET–CT scans
performed at 10–12 weeks, do not need
salvage neck dissection (R)
• Salvage surgery should be considered for
those with incomplete or equivocal response
of nodal disease on PET–CT (R)
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Management of recurrent neck disease
Prior to planning salvage treatment, the patient should be
meticulously evaluated for distant metastases. This
group is likely to benefit from PET–CT scans to look
for distant metastases. If the recurrence has occurred fol-
lowing RT or chemoradiotherapy and is surgically
resectable, surgery should be offered but acknowledge
the higher risk of complications. In patients who
present with unresectable disease, re-irradiation with or
without chemotherapy should be considered, particular-
ly in those who present more than two years since their
previous treatment. Evidence of partial repair of RT-
induced spinal cord subclinical damage and newer RT
delivery techniques (IMRT, Tomotherapy®, protons)
that allow better sparing of neurological, vascular and
soft tissue at risk make this a realistic option in a
larger number of patients. In patients who recur after pre-
vious surgical treatment, options include re-resection
followed by adjuvant radiation, or primary RT or
chemoradiotherapy.
Palliative care
Patients who have incurable nodal recurrence present a
significant challenge, particularly when distant metas-
tases are not present as people can then live with recur-
rent disease for many months or longer. Fungating
neck nodes have a significant effect on psychosocial
function. The impact on speech and swallowing
needs careful discussion with dieticians and speech
and language therapists so that the potential benefits
of tube feeding can be weighed against the risk of
over-medicalising terminal care. Specialist palliative
care teams should ideally be involved in these discus-
sions before such complications develop.
There may be occasions where palliative RT, chemo-
therapy or surgery have the potential to improve quality
of life (QoL) in this situation. The overall expected
prognosis, patient perspective and goals, morbidity of
treatment and likely benefits need to be openly dis-
cussed to ensure that there is a reasonable expectation
that any intervention will improve QoL for a given
individual.
Ongoing research
Current portfolio studies open to recruitment and rele-
vant to neck metastases include: the role of SND in
patients with early oral SCC (1–3 cm primary size)
and no clinical evidence of lymph node metastases in
the neck (SEND trial).
Key points
• The neck stage is the single most important
tumour prognostic factor
• Prognosis is affected by number of involved
nodes, the anatomic level in the neck, tumour
load, the presence of extracapsular spread, peri-
neural and vascular invasion, previous treatment
by surgery or radiotherapy and resectability
• A large number of malignant nodes will measure
less than 10 mm in diameter and extracapsular
spread will occur in a substantial percentage of
smaller nodes, as small as 2 mm. These may not
be identified on conventional (CT and magnetic
resonance) imaging
• Incidence of nodal metastases depends on site and
size of the primary tumour. This figure may be as
low as 1 per cent for early glottic tumours or as
high as 80 per cent for nasopharyngeal carcinomas
• The majority of tumours will metastasise in a pre-
dictable manner to certain nodal groups but it
should be remembered that tumours can metasta-
sise to more remote sites (i.e. nasopharyngeal
cancers to level V, tongue cancers to level IV)
and that the pattern of spread will be disrupted
by previous surgery or radiotherapy
• The possibility of bilateral nodal disease should be
considered especially when the primary site
involves the tongue base, nasopharynx or supra-
glottic larynx or when the primary site crosses
midline
• Neck dissections should be documented as per the
accepted classification system
• Radiotherapy target delineation should follow the
internationally recognised consensus guidelines
• Standardised reporting of neck dissection speci-
mens according to the Royal College of
Pathologists data set is essential
• Issues of function and quality of life have to be
considered in the management of metastatic neck
disease.
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